ImmunityBio (IBRX)
(Real Time Quote from BATS)
$2.36 USD
-0.02 (-0.84%)
Updated Aug 7, 2025 03:30 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IBRX 2.36 -0.02(-0.84%)
Will IBRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IBRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IBRX
ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
IBRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Other News for IBRX
Decoding ImmunityBio Inc (IBRX): A Strategic SWOT Insight
ImmunityBio (IBRX) Receives Continuous Buy Rating from D. Boral Capital | IBRX Stock News
ImmunityBio GAAP EPS of -$0.10 beats by $0.01, revenue of $26.43M beats by $2.38M
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With ...
ImmunityBio (IBRX) Maintains Buy Rating with $30 Price Target | IBRX Stock News